ASH 2019 | Oral time-limited duvelisib/venetoclax in R/R CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase I trial (NCT03534323) assessing duvelisib in combination with venetoclax as a possible treatment for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). Early efficacy data for this 1-year time-limited, all oral regimen are promising. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up